🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Italy / NCT07608926
Recruiting Not applicable

Cardiovascular Prevention Supported by Digital Technology: Comparison With the Traditional Model

NCT07608926 · tracked via the Priya Life Science Italy tracker
Phase
Not applicable
Started
2025-05-28
Last updated
2026-05-27

Condition(s) studied

Cardiovascular (CV) Risk

Investigational drug(s) / intervention(s)

Recommendations to the patient.

Recommendations to the patient.: Recommendations to the patient

Study summary

Cardiovascular diseases represent one of the leading causes of morbidity and mortality worldwide. Prevention in patients at cardiovascular risk is essential to reduce the incidence of cardiovascular events and slow the progression of risk.

This study aims to evaluate the effectiveness and feasibility of a cardiovascular prevention pathway delivered remotely through a digital application, comparing it with a traditional in-person care pathway.

Eligibility

Sex
ALL
Min age
40 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Age between 40 and 75 years * hypertension * hyperglycaemia * type 2 diabetes not requiring insulin therapy * dyslipidaemia * active smoking * overweight/grade I obesity * Willingness to participate in follow-up visits over 24 months Exclusion Criteria: * previous myocardial infarction * stroke * transient ischemic attack * coronary artery diseas * peripheral arterial occlusive disease * heart failure * Type 1 or type 2 diabetes mellitus on insulin therapy * Advanced chronic kidney disease (eGFR \< 30 mL/min/1.73 m²) * Active cancer disease * Severe obesity * Inability to use digital tools * Pregnancy

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Maria Cecilia Hospital Cotignola Ravenna Recruiting

More Maria Cecilia Hospital trials in Italy

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07608926 on ClinicalTrials.gov ↗ ← All trials in Italy